{"filing":{"accession_number":"0001295947-26-000029","cik":"0001295947","ticker":"PBH","company_name":"Prestige Consumer Healthcare Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"pbh-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1295947/000129594726000029/pbh-20260630.htm"},"events":[{"id":16128,"run_id":14391,"accession_number":"0001295947-26-000029","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Prestige Consumer Healthcare completed the acquisition of LaCorium Health Australia and related entities on July 1, 2026, for approximately $150 million in cash. LaCorium is a leader in Australian therapeutic skin care with approximately $40 million in annual revenue. The company entered into an amendment to its Term Loan Credit Agreement permitting an additional $95 million borrowing to finance the acquisition.","company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14124,"accession_number":"0001295947-26-000029","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 1.01 discloses entry into an amendment to the Term Loan Credit Agreement permitting the Borrower to borrow an additional $95 million to finance the previously announced acquisition of LaCorium Health Australia and related entities. The supplemental exhibits confirm completion of the LaCorium acquisition on July 1, 2026 for approximately $150 million in cash. This is a material acquisition activity that would significantly affect investor assessment of the registrant's capital structure, strategic direction, and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:06:47.422468+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14126,"accession_number":"0001295947-26-000029","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The Item 7.01 disclosure centers on the completion of the LaCorium Health acquisition (closed July 1, 2026) for approximately $150 million in cash, announced in Exhibit 99.2. While the section also mentions debt issuance ($400 million senior notes), the primary material event disclosed is the M\u0026A completion. The acquisition of LaCorium—a leader in Australian therapeutic skin care with ~$40 million annual revenue—represents a material acquisition that would affect investor assessment of the registrant's strategic direction and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:06:47.422468+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":16129,"run_id":14391,"accession_number":"0001295947-26-000029","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Prestige borrowed $95 million under an amendment to its Term Loan Credit Agreement on the LaCorium acquisition closing date (July 1, 2026), and priced a $400 million offering of 6.25% senior notes due 2034 to refinance existing 5.125% notes due 2028 and fund acquisition-related fees.","company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14125,"accession_number":"0001295947-26-000029","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 discloses the creation of a direct financial obligation: Prestige borrowed $95 million under an amendment to finance the LaCorium Acquisition on the closing date. The supplemental exhibits confirm the company priced a $400 million offering of 6.25% senior notes due 2034 to refinance existing 5.125% notes due 2028 and fund acquisition-related fees. This is a material debt issuance creating new direct financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:06:47.422468+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14124,"accession_number":"0001295947-26-000029","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 1.01 discloses entry into an amendment to the Term Loan Credit Agreement permitting the Borrower to borrow an additional $95 million to finance the previously announced acquisition of LaCorium Health Australia and related entities. The supplemental exhibits confirm completion of the LaCorium acquisition on July 1, 2026 for approximately $150 million in cash. This is a material acquisition activity that would significantly affect investor assessment of the registrant's capital structure, strategic direction, and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:06:47.422468+00:00","company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","filing_date":"2026-07-06"},{"id":14125,"accession_number":"0001295947-26-000029","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 discloses the creation of a direct financial obligation: Prestige borrowed $95 million under an amendment to finance the LaCorium Acquisition on the closing date. The supplemental exhibits confirm the company priced a $400 million offering of 6.25% senior notes due 2034 to refinance existing 5.125% notes due 2028 and fund acquisition-related fees. This is a material debt issuance creating new direct financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:06:47.422468+00:00","company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","filing_date":"2026-07-06"},{"id":14126,"accession_number":"0001295947-26-000029","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The Item 7.01 disclosure centers on the completion of the LaCorium Health acquisition (closed July 1, 2026) for approximately $150 million in cash, announced in Exhibit 99.2. While the section also mentions debt issuance ($400 million senior notes), the primary material event disclosed is the M\u0026A completion. The acquisition of LaCorium—a leader in Australian therapeutic skin care with ~$40 million annual revenue—represents a material acquisition that would affect investor assessment of the registrant's strategic direction and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:06:47.422468+00:00","company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","filing_date":"2026-07-06"}]}